Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
The FDA's Clinical Trial Diversity Initiative in the Setting of the Ongoing COVID-19 Pandemic
Session Chair(s)

Wambui Chege, MD, FACP
- Physician Policy Advisor, DMPD, OMP, CDER
- FDA, United States
FDA’s commitment to Clinical Trial (CT) diversity is integral to the agency’s mission. Recognizing that COVID-19 affects certain populations differently, FDA’s session will explore solutions and stakeholder collaborations in support of CT diversity.
Learning Objective : Describe the need to include under-represented patient populations in US clinical trials; Discuss a range of efforts to incorporate diversity into clinical trials, as well as FDA recommendations of inclusive trial practices and trial methodologies to facilitate the enrollment of broader populations.
Speaker(s)
Panelist
Richardae Araojo, PharmD, MS
- Associate Commissioner for Minority Health, Director, Office of Minority Health
- FDA, United States
Panelist
John Concato, MD, MPH, MS
- Associate Director for Real-World Evidence Analytics, OMP, CDER
- FDA, United States

Panelist
Peter Basseches, PhD
- Distinguished Scientist, Global Regulatory Affairs and Clinical Safety
- Merck & Co., Inc, United States

Panelist
Anu Osinusi, MD, MPH
- Vice President, Hepatitis, Respiratory and Emerging Viruses
- Gilead Sciences, Inc., United States

Panelist
Richard Knight, MBA
- President
- American Association of Kidney Patients , United States
Panelist
John Whyte, DrMed, MD, MPH
- Chief Medical Officer
- WebMD, United States